{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:50:53Z","timestamp":1790027453985,"version":"4.0.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272200800056C"],"award-info":[{"award-number":["HHSN272200800056C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen Vaccines & Prevention"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This phase 1 placebo-controlled study assessed the safety and immunogenicity of 2-dose regimens of Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) and MVA-BN-Filo (modified vaccinia Ankara [MVA]) vaccines with booster vaccination at day 360.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Healthy US adults (N\u2005=\u2005164) randomized into 10 groups received saline placebo or standard or high doses of Ad26 or MVA in 2-dose regimens at 7-, 14-, 28-, or 56-day intervals; 8 groups received booster Ad26 or MVA vaccinations on day 360. Participants reported solicited and unsolicited reactogenicity; we measured immunoglobulin G binding, neutralizing antibodies and cellular immune responses to Ebola virus glycoprotein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All regimens were well tolerated with no serious vaccine-related adverse events. Heterologous (Ad26,MVA [dose 1, dose 2] or MVA,Ad26) and homologous (Ad26,Ad26) regimens induced humoral and cellular immune responses 21 days after dose 2; responses were higher after heterologous regimens. Booster vaccination elicited anamnestic responses in all participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both heterologous and homologous Ad26,MVA Ebola vaccine regimens are well tolerated in healthy adults, regardless of interval or dose level. Heterologous 2-dose Ad26,MVA regimens containing an Ebola virus insert induce strong, durable humoral and cellular immune responses. Immunological memory was rapidly recalled by booster vaccination, suggesting that Ad26 booster doses could be considered for individuals at risk of Ebola infection, who previously received the 2-dose regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa586","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T15:12:39Z","timestamp":1600096359000},"page":"595-607","source":"Crossref","is-referenced-by-count":34,"title":["Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26\u2013 and Modified Vaccinia Ankara\u2013Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study"],"prefix":"10.1093","volume":"226","author":[{"given":"Neil","family":"Goldstein","sequence":"first","affiliation":[{"name":"Janssen Infectious Diseases and Vaccines , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viki","family":"Bockstal","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases and Vaccines , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Bart","sequence":"additional","affiliation":[{"name":"Optimal Research LLC , Rockville, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Luhn","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases and Vaccines , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Robinson","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases and Vaccines , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auguste","family":"Gaddah","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases and Vaccines , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Callendret","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases and Vaccines , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases and Vaccines , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"2022090418290487600_CIT0001","doi-asserted-by":"crossref","first-page":"e09015","DOI":"10.7554\/eLife.09015","article-title":"Ebola virus disease in the Democratic Republic of the Congo, 1976\u20132014","volume":"4","author":"Rosello","year":"2015","journal-title":"Elife"},{"key":"2022090418290487600_CIT0002","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"2022090418290487600_CIT0003","article-title":"Ebola virus disease distribution map: cases of Ebola virus disease in Africa since 1976","author":"Centers for Disease Control and Prevention."},{"key":"2022090418290487600_CIT0004","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1473-3099(19)30360-3","article-title":"Ebola in the Democratic Republic of the Congo: 1 year on","volume":"19","author":"Burki","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022090418290487600_CIT0005","article-title":"Ebola in the Democratic Republic of the Congo\u2014health emergency update","author":"World Health Organization"},{"key":"2022090418290487600_CIT0006","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1056\/NEJMsr1513109","article-title":"After Ebola in West Africa\u2014unpredictable risks, preventable epidemics","volume":"375","author":"WHO Ebola Response Team.","year":"2016","journal-title":"N Engl J Med"},{"key":"2022090418290487600_CIT0007","doi-asserted-by":"crossref","first-page":"20160295","DOI":"10.1098\/rstb.2016.0295","article-title":"A review of phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?","volume":"372","author":"Lambe","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2022090418290487600_CIT0008","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2022090418290487600_CIT0009","article-title":"Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response","author":"World Health Organization"},{"key":"2022090418290487600_CIT0010","article-title":"Vaccine against Ebola: Commission grants first-ever market authorisation","author":"European Commission"},{"key":"2022090418290487600_CIT0011","article-title":"First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response","author":"Food and Drug Administration"},{"key":"2022090418290487600_CIT0012","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"2022090418290487600_CIT0013","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1128\/IAI.00740-09","article-title":"Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses","volume":"78","author":"Reyes-Sandoval","year":"2010","journal-title":"Infect Immun"},{"key":"2022090418290487600_CIT0014","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS One"},{"key":"2022090418290487600_CIT0015","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O\u2019Hara","year":"2012","journal-title":"J Infect Dis"},{"key":"2022090418290487600_CIT0016","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"2022090418290487600_CIT0017","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med"},{"key":"2022090418290487600_CIT0018","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J Virol"},{"key":"2022090418290487600_CIT0019","doi-asserted-by":"crossref","first-page":"e44115","DOI":"10.1371\/journal.pone.0044115","article-title":"Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species","volume":"7","author":"Zahn","year":"2012","journal-title":"PLoS One"},{"key":"2022090418290487600_CIT0020","article-title":"2015 Janssen Ebola vaccine: emergency track program. Review of Ebola vaccines in phase 1 clinical evaluation","author":"Van Hoof"},{"key":"2022090418290487600_CIT0021","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J Infect Dis"},{"key":"2022090418290487600_CIT0022","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J Infect Dis"},{"key":"2022090418290487600_CIT0023","article-title":"Vaccine against Ebola: Commission grants new market authorizations","author":"European Commission"},{"key":"2022090418290487600_CIT0024","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J Clin Invest"},{"key":"2022090418290487600_CIT0025","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa586\/34068923\/jiaa586.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/4\/595\/45689161\/jiaa586.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/4\/595\/45689161\/jiaa586.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T14:30:46Z","timestamp":1662301846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/4\/595\/5906668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,9,16]]},"published-print":{"date-parts":[[2022,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa586","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,15]]},"published":{"date-parts":[[2020,9,16]]}}}